PPIDT00303
Drug Information
| Name | Setmelanotide |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB11700 |
| Type | small molecule |
| Indication | Setmelanotide is indicated for chronic weight management in patients 6 years and older with obesity due to pro-opiomelanocortin (POMC) deficiency, proprotein subtilisin/kexin type 1 (PCSK1) deficiency, or leptin receptor (LEPR) deficiency as determined by an approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance.[L42130, L43483, L46327] These conditions affect the MC4R signalling pathway.[A224454] Setmelanotide is also indicated for chronic weight management in patients 6 years and older with obesity due to Bardet-Biedl syndrome.[L42130, L43483, L46327] The drug is not reported to be effective in patients with POMC, PCSK1, or LEPR variants classified as benign or likely benign, as well as other types of obesity not listed above.[L46327] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Subcutaneous |
10 MG/ML
|
| Solution | Subcutaneous |
10 mg / mL
|
| Solution | Subcutaneous |
10 mg/1mL
|